Immunis, Inc. is a biotechnology company specializing in developing advanced therapeutic solutions for treating age-related immune decline and diseases. The company, established in 2019, is headquartered in Irvine, California. Immunis focuses primarily on developing secretome products that target immune dysfunction related to aging, offering regenerative solutions to enhance human health. The company was founded by renowned stem cell expert Dr. Hans Keirstead, who serves as its Chairman.
| Attribute | Information |
|---|---|
| Founding Date | 2019 |
| Headquarters | Irvine, California, USA |
| Founders | Dr. Hans Keirstead |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Remiges Ventures, others |
| Industry | Biotechnology |
| Number of Employees | Approximately 50 |
Immunis was founded in 2019 by Dr. Hans Keirstead, who brought extensive experience in stem cell research and biotechnology innovations. The company quickly made strides in developing secretome-based therapies aimed at overcoming age-related immune dysfunction. This focus on rejuvenating the immune system was driven by the growing recognition of immune health’s critical role in aging populations. Immunis initially concentrated on researching natural human-derived products that could combat conditions like muscle atrophy and other degenerative diseases associated with aging. As scientific interest in cellular and genetic therapies grew, Immunis’ foundational strategies positioned it well to leverage these advancements and expand their impact in the biotech sector.
Immunis operates a business model focused on research and development of biotechnology products aimed at redefining age-associated immune treatment. Their investigative product line emphasizes naturally sourced secretomes, showcasing significant promise in pre-clinical trials.
Immunis is advancing towards completing later-stage clinical trials for its primary product, IMMUNA. The company’s strategic initiatives include forming alliances with pharmaceutical giants like Toray to augment their R&D capabilities. Immunis is posited as a leader in regenerative health, exerting influence in the biotech market with innovative therapies that address growing demographic health challenges. Their market position is strengthened by substantial financial backing and an expanding portfolio addressing unmet medical needs.
Immunis, Inc. continues to play a pivotal role in the biotechnology sphere, particularly in addressing the challenges posed by age-related immune degeneration. With a commitment to enhancing the quality of life through innovative secretome therapies, the company is well-positioned to make significant contributions to the field of regenerative medicine. Looking ahead, Immunis aims to expand its clinical applications, and continues to build partnerships that will further its mission to transform treatment landscapes for age-associated diseases, reinforcing its reputation as a biotechnology pioneer.